N/A
N=139
Correlation Between Cognitive Function and Relapse of Schizophrenia Regarding Dose Reduction
Schizophrenia Relapse
Bottom Line
View on ClinicalTrials.gov: NCT03019887 ↗Enrolled (actual)
139
Serious AEs
0.0%
Results posted
Sep 2021
Primary outcome: Primary: Number of Participants With Relapse — 130 Participants
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- reduction of risperidone, haloperidol, olanzapine, quetiapine, aripiprazole, paliperidone, levomepromazine, perphenazine (Drug)
- Age
- Adult, Older Adult · 20+ yrs
- Sex
- All
- Sponsor
- Juntendo University
- Primary completion
- Jan 2017
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants With Relapse |
130 | — |
Summary
To reduce antipsychotics to under 1000mg in patients with schizophrenia taking more than 1000mg/day and to evaluate relationship between relapse and cognitive function.
Eligibility Criteria
Inclusion Criteria
- inpatients with a diagnosis of schizophrenia, and
- those in the chronic phase receiving mean daily antipsychotic doses exceeding 1000-mg chlorpromazine eq./day.
Exclusion Criteria
- mental retardation,
- substance abuse or dependence,
- a history of major head trauma,
- serious medical or neurological disorders, or
- depot antipsychotic injections within the previous 3 months and electroconvulsive therapy within the previous 6 months
Data sourced from ClinicalTrials.gov (NCT03019887). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.